ANNOUNCEMENT

Take a look at the MedCity ENGAGE program, with expert speakers from leading organizations. Reserve your place today.

Topic: JNJ

Big pharma companies’ R&D collaboration could reduce drug development costs

Big pharma companies’ R&D collaboration could reduce drug development costs

September 19, 2012 5:38 pm by | 0 Comments

A group of 10 big pharma companies are collaborating in a move that could change the way clinical trials are done. One goal of the nonprofit will be to provide ... Read more
J&J to open innovation centers in London, China, U.S. to hunt for novel, early stage deals

J&J to open innovation centers in London, China, U.S. to hunt for novel, early stage deals

September 18, 2012 4:55 pm by | 0 Comments

In a move to gain access to early stage innovation, Johnson & Johnson (NYSE:JNJ) is opening innovation centers in Europe and China as well as in Boston. Earlier this year, ... Read more
Will Pfizer, J&J’s failed Alzheimer’s drug someday be a pre-Alzheimer’s drug?

Will Pfizer, J&J’s failed Alzheimer’s drug someday be a pre-Alzheimer’s drug?

August 7, 2012 6:41 pm by | 0 Comments

Pfizer and Johnson & Johnson's Alzheimer's drug failed to help patients showing early signs of the disease, but it could get another chance as scientists test whether the devastating illness ... Read more
CONVERGE product demonstration: Janssen Healthcare Innovation

CONVERGE product demonstration: Janssen Healthcare Innovation

July 11, 2012 1:20 pm by | 0 Comments

One theory behind improving patient adherence is it’s a question of memory and helping people stay better organized. For people who may be taking several medications at once, missing one ... Read more
FDA says no to J&J’s Xarelto for acute coronary syndrome … for now

FDA says no to J&J’s Xarelto for acute coronary syndrome … for now

June 21, 2012 8:40 pm by | 0 Comments

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson (NYSE:JNJ) drug Xarelto to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome, ... Read more
Will Janssen’s new class of type 2 diabetes drug fare better than AZN?

Will Janssen’s new class of type 2 diabetes drug fare better than AZN?

May 31, 2012 4:00 pm by | 0 Comments

Janssen, a division of Johnson & Johnson (NYSE:JNJ) has submitted a new drug application for canagliflozin that belongs to a new class of drugs called SGLT2 inhibitors to treat type ... Read more
J&J unit feels FDA heat over handling of K-Y Jelly product complaints

J&J unit feels FDA heat over handling of K-Y Jelly product complaints

May 29, 2012 7:15 pm by | 0 Comments

A Johnson & Johnson (NYSE:JNJ) division for the company’s tampon, lubricant and dental floss business has drawn heat from the U.S. Food and Drug Administration over its handling of medical ... Read more
FDA turns down higher dosage for HIV drug Prezista

FDA turns down higher dosage for HIV drug Prezista

May 29, 2012 2:59 pm by | 0 Comments

An application for a higher dosage of an FDA-approved HIV drug from Janssen Pharmaceuticals has been turned down by the U.S. Food and Drug Administration, according to a company statement.The ... Read more
J&J and Medtronic have contrasting acquisition strategies. Can both win?

J&J and Medtronic have contrasting acquisition strategies. Can both win?

May 7, 2012 2:22 pm by | 0 Comments

Johnson and Johnson’s (NYSE:JNJ) CEO Alex Gorsky is apparently shopping around for medical device companies to boost sagging sales in its Cardiovascular Division.A Bloomberg story highlights how some analysts believe ... Read more
FDA approves Levaquin to combat pneumonic plague bioterrorist attack

FDA approves Levaquin to combat pneumonic plague bioterrorist attack

April 27, 2012 4:45 pm by | 2 Comments

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson’s (NYSE: JNJ) antibiotic Levaquin against pneumonic plague in the event of a bioterrorist attack through ... Read more
Johnson & Johnson’s Q1 performance paints a mixed picture

Johnson & Johnson’s Q1 performance paints a mixed picture

April 17, 2012 3:49 pm by | 0 Comments

Despite encouraging sales performance in the first quarter for recently approved oncology drugs, Johnson & Johnson (NYSE:JNJ) continues to be vexed by manufacturing problems. That, coupled with new questions over ... Read more
Johnson & Johnson is scouting for a new project to reuse AIDS strategy

Johnson & Johnson is scouting for a new project to reuse AIDS strategy

April 13, 2012 9:09 am by | 1 Comments

Johnson & Johnson (NYSE:JNJ) spent a lot of time talking partnerships at the 2012 TEDMED conference. And a company executive said that if there’s one approach the company would look ... Read more
Johnson & Johnson vice chair resigns for top job at Avon

Johnson & Johnson vice chair resigns for top job at Avon

April 9, 2012 2:27 pm by | 0 Comments

Sherilyn McCoy, a vice chairman of the Johnson & Johnson (NYSE:JNJ) executive committee, has resigned to take the top job at cosmetics firm Avon.McCoy had been with the New Brunswick, ... Read more
Bioterrorism threat spurs authorities to invoke animal rule for J&J antibiotic

Bioterrorism threat spurs authorities to invoke animal rule for J&J antibiotic

April 5, 2012 5:44 pm by | 2 Comments

The U.S. Food and Drug Administration, is reviewing whether to approve an expanded use of Johnson & Johnson‘s (NYSE: JNJ) antibiotic Levaquin to treat pneumonic plague, despite the fact that ... Read more
Xarelto could set a new standard for treating pulmonary embolisms

Xarelto could set a new standard for treating pulmonary embolisms

March 27, 2012 11:53 am by | 0 Comments

Johnson & Johnson (NYSE:JNJ) subsidiary Janssen Pharamceuticals’ drug Xarelto, an anticoagulant that has produced positive phase 3 results to treat clots in the lung in a recent study, could set ... Read more